SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.

Q3 Medicine Acta medica academica Pub Date : 2023-04-01 DOI:10.5644/ama2006-124.399

Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan, Robert H Collins, Olga K Weinberg, Alagarraju Muthukumar, Stephen S Chung, Yazan F Madanat

{"title":"SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.","authors":"Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan, Robert H Collins, Olga K Weinberg, Alagarraju Muthukumar, Stephen S Chung, Yazan F Madanat","doi":"10.5644/ama2006-124.399","DOIUrl":null,"url":null,"abstract":"Objective: Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.Methods: Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.Results: Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.Conclusion: Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"52 1","pages":"30-36"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/2b/AMA-52-30.PMC10316070.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica academica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5644/ama2006-124.399","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.

Methods: Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.

Results: Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.

Conclusion: Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨髓富集队列血液恶性肿瘤患者的SARS-CoV-2疫苗IgG抗体反应:单中心观察

目的:诊断为血液系统恶性肿瘤的患者发生严重SARS-CoV-2感染的风险增加。我们评估了血液系统恶性肿瘤患者接种两剂SARS-CoV-2疫苗后血清IgG反应。方法:在德克萨斯大学西南医学中心诊断为髓系或淋巴系肿瘤的患者纳入研究。SARS-CoV-2疫苗接种应答定义为可量化的刺突IgG抗体滴度阳性。结果:60例患者被纳入研究，其中60%被诊断为髓系肿瘤。大多数(85%)髓系恶性肿瘤患者和50%淋巴系恶性肿瘤患者在接种两剂疫苗后出现血清学应答。结论:无论正在进行的治疗或活动性疾病，都应提供疫苗接种。研究结果需要在更大的患者队列中进行验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊